UNSPSC 51171610: Senna glycosides or sennosides

This classification denotes a laxative, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3FYP5M0IJX. European Medicines Agency schedules Sennosides in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB40994. Sennosides generally arises in the molecular formula C42H38O20. The term 'sennosides' is a U.S. Pharmacopeial Convention designation. Senna glycosides or sennosides bears US NLM identifiers UMLS ID C0074332 and NCI Concept Code C29448.

SMILES: C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O.

UNSPSC 51171610 Senna glycosides or sennosides is a Commodity code that captures laxative and bowel-preparation pharmaceutical products procured by state and local health and human services agencies. The recent opportunities under this code do not reflect direct purchasing of senna or sennoside products themselves; instead, they reveal how state and local government procurement offices classify pharmaceutical and laboratory-testing services within their broader taxonomy. The code appears to be assigned to opportunities involving pharmacy benefit management, drug testing, and generic pharmaceutical distribution channels rather than discrete senna-containing formulations.

The issuing bodies active under this code span state health commissions, county criminal justice and corrections departments, and multistate cooperative purchasing alliances. Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs; Collin County Community Supervision and Corrections Department released RFP 2026-327 in July 2026 for offender drug testing services with a $600,000 estimated contract value and July 23, 2026 response deadline; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Activity is concentrated in Texas and Minnesota, with MMCAP serving a multistate footprint. The mismatch between the code's nominal scope (senna glycosides) and the actual work being solicited (drug testing operations, pharmacy benefit program design, and generic pharmaceutical distribution) suggests this code may be a classification artifact; firms pursuing contracts under this commodity would see limited relevance to direct senna-product supply.